Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: A phase II north central cancer treatment group clinical trial

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 4, 2012, Pages 329-333

  Alberts, Steven Robert ^a   Fitch, Tom R ^b   Kim, George P ^c   Morlan, Bruce W ^a   Dakhil, Shaker R ^d   Gross, Howard M ^e   Nair, Suresh ^f  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^e Hematology and Oncology of Dayton   (United States)

^f LEHIGH VALLEY HOSPITAL   (United States)

Author keywords

AZD2171; cediranib; hepatocellular carcinoma; phase II; VEGF

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; CEDIRANIB; ERLOTINIB; SORAFENIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER CIRRHOSIS; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE MONITORING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; ECHOGRAPHY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEMATOLOGICAL PARAMETERS; HEMOCHROMATOSIS; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; LABORATORY TEST; LEG WEAKNESS; LIVER CELL CARCINOMA; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROTEINURIA; PRURITUS; SIDE EFFECT; SOMNOLENCE; STOMATITIS; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; URINALYSIS; VALVULAR HEART DISEASE; VOMITING; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; QUINAZOLINES; SURVIVAL RATE;

EID: 84864348077     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182118cdf     Document Type: Article

References (14)

1. Mathurin P, Rixe O, Carbonell N, et al. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma- an impossible meta-analysis? Aliment Pharmacol Ther. 1998;12: 111-126. (Pubitemid 28059978)
2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Eng J Med. 2008;359:378-390.
3. Poon RT-P, Lau CP-Y, Cheung S-T, et al. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res. 2003;63:3121-3126. (Pubitemid 36735862)
4. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65:4389-4400. (Pubitemid 40775678)
5. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nature Rev Clin Oncol. 2009;6:327-338.
6. Tabernero J. The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res: MCR. 2007;5:203-220. (Pubitemid 46569773)
7. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917. (Pubitemid 37518510)
8. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38:143-151.
9. Kaplan E PM. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457-481.
10. Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007;25:3045-3054. (Pubitemid 47218051)
11. Yamamoto N, Tamura T, Yamamoto N, et al. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009;64:1165-1172.
12. Ryan CJ, Stadler WM, Roth B, et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Investigational New Drugs. 2007;25:445-451. (Pubitemid 47222908)
13. Cheng A-L, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
14. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009; 27:843-850.